Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2019.
Highlights:
- Revenue up 6% to £9.3 million
- Profit before tax up 1% to £7.0 million
- Cash down £0.5 million to £6.5 million
- Second interim dividend of 43p per share (2018: 36p)
- Special dividend of 47p per share (2018: 55p)
bioventix